CN1863773A - 四氢吡啶衍生物 - Google Patents

四氢吡啶衍生物 Download PDF

Info

Publication number
CN1863773A
CN1863773A CNA2004800293878A CN200480029387A CN1863773A CN 1863773 A CN1863773 A CN 1863773A CN A2004800293878 A CNA2004800293878 A CN A2004800293878A CN 200480029387 A CN200480029387 A CN 200480029387A CN 1863773 A CN1863773 A CN 1863773A
Authority
CN
China
Prior art keywords
phenyl
heteroaryl
chloro
general formula
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800293878A
Other languages
English (en)
Chinese (zh)
Inventor
奥利维尔·贝曾康
蒂埃里·西费朗
丹尼尔·比尔
瓦尔特·菲施利
托马斯·韦勒
尤博斯·雷门
西尔维娅·理查德-比洛斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1863773A publication Critical patent/CN1863773A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800293878A 2003-10-09 2004-10-05 四氢吡啶衍生物 Pending CN1863773A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0311146 2003-10-09
EPPCT/EP03/11146 2003-10-09

Publications (1)

Publication Number Publication Date
CN1863773A true CN1863773A (zh) 2006-11-15

Family

ID=34486009

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800293878A Pending CN1863773A (zh) 2003-10-09 2004-10-05 四氢吡啶衍生物

Country Status (6)

Country Link
US (1) US20080234305A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007508260A (cg-RX-API-DMAC7.html)
CN (1) CN1863773A (cg-RX-API-DMAC7.html)
AU (1) AU2004283814A1 (cg-RX-API-DMAC7.html)
CA (1) CA2540543A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005040120A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101696187B (zh) * 2009-09-30 2011-09-07 徐州工业职业技术学院 N-取代基-1,2,3,6-四氢吡啶的合成方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE462703T1 (de) * 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
AU2006272348B2 (en) * 2005-07-22 2011-06-16 Merck Frosst Canada Ltd Renin inhibitors
AR058885A1 (es) 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
ZA200808419B (en) * 2006-03-03 2009-12-30 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
CL2007000595A1 (es) * 2006-03-08 2008-01-04 Actelion Pharmaceuticals Ltd Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
ES2541107T3 (es) 2007-06-25 2015-07-16 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina
AU2008288648A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
MX2010005283A (es) 2007-12-05 2010-05-27 Basf Se Compuestos de piridilmetil-sulfonamida.
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
PL2274295T3 (pl) 2008-05-05 2016-01-29 Idorsia Pharmaceuticals Ltd 3,4–podstawione pochodne piperydyny jako inhibitory reniny
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
EP2640699B1 (en) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
IL151164A0 (en) * 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
US20030013883A1 (en) * 2000-06-16 2003-01-16 Tamagnan Gilles D. Tropane analogs binding to monoamine transporters
MXPA04010608A (es) * 2002-04-29 2004-12-13 Actelion Pharmaceuticals Ltd Derivados de 7-aril-3,9-diazabiciclo(3.3.1)non-6-eno y sus usos como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales.
EP1519920A1 (en) * 2002-06-27 2005-04-06 Actelion Pharmaceuticals Ltd. Novel tetrahydropyridine derivatives as renin inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101696187B (zh) * 2009-09-30 2011-09-07 徐州工业职业技术学院 N-取代基-1,2,3,6-四氢吡啶的合成方法

Also Published As

Publication number Publication date
WO2005040120A1 (en) 2005-05-06
CA2540543A1 (en) 2005-05-06
US20080234305A1 (en) 2008-09-25
AU2004283814A1 (en) 2005-05-06
JP2007508260A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
CN1863773A (zh) 四氢吡啶衍生物
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1310917C (zh) 趋化因子受体活性的四氢吡喃基环戊基四氢吡啶并吡啶调节剂
CN1028103C (zh) 哌啶基苯并咪唑类化合物的制备方法
CN1802376A (zh) Cgrp受体拮抗剂
CN1780663A (zh) 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物
CN1890239A (zh) 二氮杂二环壬烯及带有新的侧链的四氢吡啶衍生物
CN1349524A (zh) 血管紧张肽原酶抑制剂
JP2010527942A (ja) 新規類のレニン阻害剤
CN1780836A (zh) 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
CN1780837A (zh) 新型氮杂二环壬烯衍生物
CN1780838A (zh) 新型二氮杂双环壬烯衍生物
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
JP2012511514A (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
CN1867568A (zh) 二氮杂二环壬烯衍生物及其作为血管紧张肽原酶抑制剂的用途
CN1780833A (zh) 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
CN1897941A (zh) 趋化因子受体活性的烷基氨基、芳基氨基以及氨磺酰基环戊基酰胺调节剂
KR100963455B1 (ko) 신규한 피페리딘 카르복실산 아미드 유도체
CN1909906A (zh) 作为趋化因子受体活性调节剂的2,6－二取代的哌啶类化合物
CN1167682C (zh) 毒蕈碱拮抗剂
CN1311785A (zh) 作为甘氨酸拮抗剂的四氢喹啉衍生物
CN1890240A (zh) 二氮杂二环壬烯衍生物及其作为血管紧张肽原酶抑制剂的用途
CN1210273C (zh) 取代的3－吡啶基－4－芳基吡咯及治疗和预防相关疾病的方法
CN1662504A (zh) 2,5－二取代的3－巯基戊酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication